Globe Newswire

Austin, TX, May 17, 2024 (GLOBE NEWSWIRE) -- Digital Brands Group, Inc. (“DBG”) (NASDAQ: DBGI), a curated collection of luxury lifestyle, digital-first brands, will report financial results for the first quarter ended March 30, 2024 on Monday, May 20, 2024 at 9:30 a.m. ET.

Management will host a conference call on Monday, May 20, 2024 at 10:30 a.m. ET to discuss the results. The live conference call can be accessed by dialing 888-506-0062 from the U.S. or... (continue reading...)

MONTREAL, May 17, 2024 (GLOBE NEWSWIRE) -- mdf commerce inc. (“mdf” or the “Company”) (TSX: MDF), a SaaS leader in digital commerce technologies, is pleased to announce the closing of the previously announced plan of arrangement under the Canada Business Corporations Act (the “Arrangement”) involving the Company and an entity affiliated with funds managed by KKR, a leading global investment firm.

“Today’s announcement is a significant milestone in... (continue reading...)

MCMINNVILLE, Tenn., May 17, 2024 (GLOBE NEWSWIRE) -- Security Bancorp, Inc. (OTCBB:SCYT.OB) announced that the Corporation’s Board of Directors has declared an annual cash dividend of $1.00 per share on the Corporation’s outstanding common stock. The cash dividend will be payable on July 1, 2024 to shareholders of record as of the close of business on June 3, 2024.

Security Bancorp, Inc. is the holding company for Security Federal Savings Bank of McMinnville, TN... (continue reading...)

Washington, DC, May 17, 2024 (GLOBE NEWSWIRE) -- The joint venture of Rockefeller Group and Stonebridge today joined Clark Construction and their building crews to celebrate the topping out of 600 Fifth Street NW, the only new office building under construction in Washington, D.C. that is set to deliver over the next two years.

The 400,000-square-foot building, which is 50 percent pre-leased, is taking shape on the site of the former eight-story Metro headquarters.... (continue reading...)

Phase 1b clinical trial of KM-001 demonstrated favorable safety profile and high responder rate of 87% in patients with palmoplantar keratoderma and pachyonychia congenita

In vitro and in vivo data of KM-001 and KM-023 demonstrated significant improvements in skin histology and significant reductions in scratching

NESS ZIONA, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- Kamari Pharma, a privately-held clinical stage biotechnology company developing first and... (continue reading...)